vs
Side-by-side financial comparison of Mind Medicine (MindMed) Inc. (DFTX) and Future Vision II Acquisition Corp. (FVN). Click either name above to swap in a different company.
Mind Medicine (MindMed) Inc. is the larger business by last-quarter revenue ($906.0K vs $584.4K, roughly 1.6× Future Vision II Acquisition Corp.). Future Vision II Acquisition Corp. runs the higher net margin — 86.8% vs -2634.0%, a 2720.8% gap on every dollar of revenue.
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
Future Vision II Acquisition Corp is a special purpose acquisition company formed to pursue mergers, asset acquisitions, or business combinations with high-growth enterprises. It targets technology, consumer, and sustainable industry segments across North American and Asia-Pacific markets to drive long-term shareholder value.
DFTX vs FVN — Head-to-Head
Income Statement — Q4 FY2023 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $906.0K | $584.4K |
| Net Profit | $-23.9M | $507.0K |
| Gross Margin | — | — |
| Operating Margin | -2450.8% | -14.4% |
| Net Margin | -2634.0% | 86.8% |
| Revenue YoY | -16.1% | — |
| Net Profit YoY | -386.7% | — |
| EPS (diluted) | $-0.58 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $584.4K | ||
| Q3 25 | — | $618.7K | ||
| Q2 25 | — | $614.4K | ||
| Q1 25 | — | $612.4K | ||
| Q3 24 | — | $147.8K | ||
| Q4 23 | $906.0K | — | ||
| Q3 23 | $1.2M | — | ||
| Q2 23 | $1.3M | — |
| Q4 25 | — | $507.0K | ||
| Q3 25 | — | $557.2K | ||
| Q2 25 | — | $551.9K | ||
| Q1 25 | — | $454.3K | ||
| Q3 24 | — | $141.9K | ||
| Q4 23 | $-23.9M | — | ||
| Q3 23 | $-17.9M | — | ||
| Q2 23 | $-29.1M | — |
| Q4 25 | — | -14.4% | ||
| Q3 25 | — | -11.2% | ||
| Q2 25 | — | -11.5% | ||
| Q1 25 | — | -27.3% | ||
| Q3 24 | — | -4.5% | ||
| Q4 23 | -2450.8% | — | ||
| Q3 23 | -1858.6% | — | ||
| Q2 23 | -2226.1% | — |
| Q4 25 | — | 86.8% | ||
| Q3 25 | — | 90.1% | ||
| Q2 25 | — | 89.8% | ||
| Q1 25 | — | 74.2% | ||
| Q3 24 | — | 96.0% | ||
| Q4 23 | -2634.0% | — | ||
| Q3 23 | -1541.1% | — | ||
| Q2 23 | -2222.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q4 23 | $-0.58 | — | ||
| Q3 23 | $-0.45 | — | ||
| Q2 23 | $-0.76 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $99.7M | $61.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $78.1M | $1.8M |
| Total Assets | $124.5M | $62.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $61.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $1.3M | ||
| Q4 23 | $99.7M | — | ||
| Q3 23 | $117.7M | — | ||
| Q2 23 | $116.9M | — |
| Q4 25 | — | $1.8M | ||
| Q3 25 | — | $3.1M | ||
| Q2 25 | — | $4.3M | ||
| Q1 25 | — | $7.0M | ||
| Q3 24 | — | $6.7M | ||
| Q4 23 | $78.1M | — | ||
| Q3 23 | $96.0M | — | ||
| Q2 23 | $106.0M | — |
| Q4 25 | — | $62.1M | ||
| Q3 25 | — | $61.6M | ||
| Q2 25 | — | $61.0M | ||
| Q1 25 | — | $60.4M | ||
| Q3 24 | — | $59.4M | ||
| Q4 23 | $124.5M | — | ||
| Q3 23 | $141.6M | — | ||
| Q2 23 | $142.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-20.6M | $-99.4K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.20× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-99.4K | ||
| Q3 25 | — | $-7.1K | ||
| Q2 25 | — | $-11.2K | ||
| Q1 25 | — | $-190.1K | ||
| Q3 24 | — | — | ||
| Q4 23 | $-20.6M | — | ||
| Q3 23 | $-16.6M | — | ||
| Q2 23 | $-13.8M | — |
| Q4 25 | — | -0.20× | ||
| Q3 25 | — | -0.01× | ||
| Q2 25 | — | -0.02× | ||
| Q1 25 | — | -0.42× | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
